Consolidating the Digital Slide: How Agilent's $270M Proscia Acquisition Signals the End of Standalone Pathology AI
Dr. Dereck Mush, MD, MBA
Good morning, HealthTech insiders. The next contest in HealthTech is taking place inside the workflow. A pathology platform has to work with the laboratory's scanners. An AI assistant has to bring useful information into the clinical encounter. A surgical robot has to fit the room and the team around it. Integration is becoming part of the product's value proposition, and today's announcements put three different approaches under the spotlight.
Agilent has agreed to buy Proscia in a deal worth up to $270 million. Suki has announced $90 million in Series E financing after launching Ask with UpToDate Expert AI. And J&J says it has signed OTTAVA's first commercial customer following July's FDA authorization. The direction is clear; the evidence for better care and lower costs still has to follow.
In today's Signal:
Agilent agrees to acquire Proscia for up to $270M: A pending deal combines pathology instruments and reagents with an open digital workflow platform.
Suki announces $90M Series E: Its recently launched Ask feature brings patient-chart context and UpToDate evidence into one clinician-facing interface.
OTTAVA signs its first commercial customer: J&J's October update marks early commercialization following FDA De Novo authorization in July.
Soufflé closes $135M Series B: Juvia Group leads financing to move cell-targeted RNA programs toward clinical studies.
In partnership with
7 Stocks Built to Hold Forever. See the Full List.
Chasing the next hot stock can be exhausting, and it rarely builds wealth the way investors expect. The strongest long-term portfolios are often anchored by durable, blue-chip businesses designed to withstand recessions, inflation and shifting market leadership.
MarketBeat’s free 7 Stocks to Buy and Hold Forever report identifies companies across technology, retail, consumer staples, healthcare, networking, sporting goods and utilities. Each offers its own mix of stability, income, growth and staying power.
These are not speculative names built around the latest headline. They are established businesses selected for investors who would rather own quality companies for years than constantly chase the market.
Get your complimentary copy and see all seven names today.
COMMERCIAL M&A
1. Agilent Agrees to Acquire Proscia for Up to $270M
Digital pathology workflow imagery from Proscia. Credit: Proscia.
Agilent Technologies (NYSE: A) announced on October 13 that it has agreed to acquire Proscia for $240 million at closing and up to $30 million tied to future performance milestones. Closing remains subject to customary conditions and is expected early in Agilent's fiscal 2027.
The details:
Proscia's Concentriq platform connects slide images and laboratory workflows. Concentriq AP-Dx has FDA 510(k) clearance for primary diagnosis with specified compatible equipment. August's clearance added the Leica Aperio GT 450 DX scanner, cloud deployment and a Predetermined Change Control Plan; platform clearance does not automatically cover every connected AI algorithm.
The proposed combination builds on Agilent and Proscia's 2022 distribution partnership and could support biomarker research, companion diagnostics and clinical pathology workflows.
Agilent CEO Padraig McDonnell and Proscia co-founder and CEO David West describe a shared commitment to open, digital pathology. That direction matters to laboratories using equipment from several vendors, but future interoperability must be demonstrated in practice.
The Signal: The deal shows how valuable the workflow around an algorithm can become. Agilent could bring software closer to its pathology instruments, reagents and customers. For laboratories, the test is whether that integration improves everyday work while preserving equipment choice. It does not establish the end of independent pathology AI.
CLINICAL AI
2. Suki Announces $90M Series E After Ask Launch
Suki’s clinician-facing product interface. Credit: Suki.
Suki announced $90 million in financing as part of its Series E on October 13, backing its expansion across clinical, revenue-cycle and operational workflows.
The details:
New investors include Healthier Capital, Crosslink Capital and Hercules Capital, alongside existing institutional backers. Existing participants include Venrock, Flare Capital Partners, Hedosophia, Philips Ventures and Zoom Ventures.
Suki reports serving more than 450 healthcare organizations and working with more than 30 technology partners. Its model combines a clinician-facing application with AI embedded in partner platforms.
Ask launched on October 8. It retrieves patient-specific information and synthesizes clinical content through Wolters Kluwer's UpToDate Expert AI. Suki explicitly describes it as an information retrieval and synthesis tool: it does not diagnose patients or prescribe treatment plans, and clinicians remain responsible for decisions.
The Signal: Bringing chart context and clinical evidence together could reduce the searching that interrupts an encounter. That is a useful expansion beyond documentation. The funding supports a broader ambition; it does not prove autonomous clinical reasoning, error-free answers or a guaranteed return on investment.
SURGICAL ROBOTICS
3. OTTAVA Signs Its First Commercial Customer
Johnson & Johnson’s table-integrated OTTAVA robotic surgical system. Credit: Johnson & Johnson
In its October 13 earnings update, Johnson & Johnson reported signing OTTAVA's first commercial customer. FDA De Novo authorization was granted on July 21 and announced on July 22, so this is a commercialization milestone rather than a new regulatory decision.
The details:
OTTAVA integrates four robotic arms into its operating table. J&J describes synchronized table-and-arm movement and a reduced footprint relative to traditional systems. The complete system still occupies space and requires installation and team training.
The authorization covers 10 specified general-surgery procedures, including gastric bypass, sleeve gastrectomy, cholecystectomy and hiatal hernia repair. It does not establish unrestricted multi-specialty use.
J&J says an inguinal-hernia IDE trial is underway and plans future development in urology and gynecology. Those expansion plans are distinct from the current authorized indications.
The Signal: OTTAVA brings a different physical architecture into commercial surgical robotics. Hospitals now need evidence about setup, access, training and case economics in their own operating rooms. A smaller footprint is a design advantage to evaluate; faster turnover and lower total costs remain outcomes to prove.
Related reading
Dr. Dereck Mush, MD, MBA
The Table-Integrated OR: How J&J OTTAVA's FDA Clearance Challenges Intuitive's Soft-Tissue Monopoly
Dr. Dereck Mush, MD, MBA
Beyond the Scribe: How Ambient AI Is Morphing into Point-of-Care Clinical Reasoning and EHR Operating Systems
Dr. Dereck Mush, MD, MBA
The Web Summit Dual-Track Playbook: Navigating FDA Clearance and CE-MDR Simultaneously in 2026
Dr. Dereck Mush, MD, MBAKeep exploring